newsfilter
← Latest News
GlobeNewswire·

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE